Drug Profile
TA 7906
Alternative Names: M-5200; TA-7906Latest Information Update: 09 Aug 2019
Price :
$50
*
At a glance
- Originator Tanabe Seiyaku
- Developer Mitsubishi Tanabe Pharma Corporation
- Class Anti-inflammatories; Skin disorder therapies
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atopic dermatitis
Most Recent Events
- 09 Aug 2019 Discontinued - Phase-II for Atopic dermatitis in Japan (Topical)
- 09 Sep 2015 Phase-II development is ongoing in Japan
- 30 Jun 2012 Phase-II clinical trials in Atopic dermatitis in Japan (Topical)